From a letter to the legislature dated March 6, 2016, President Kaler writes:
"We also are concerned about the House proposal to require the state's mental health and developmental disabilities ombudsman to monitor the treatment of individuals participating in University of Minnesota Department of Psychiatry clinical drug trials. As I have said in my testimony at the Capitol, the University is committed to upholding the highest ethical standards in research practices involving human participants. We continue to report monthly to the legislature on the progress in implementing our work plan to improve research with human participants. We suggest the provision is not necessary."